An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Public ClinicalTrials.gov record NCT02589717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.
Study identification
- NCT ID
- NCT02589717
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2015
- Primary completion
- Jul 31, 2016
- Completion
- Jul 31, 2016
- Last update posted
- Nov 1, 2016
2015 – 2016
United States locations
- U.S. sites
- 40
- U.S. states
- 24
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85258 | — |
| Not listed | Tucson | Arizona | 85710 | — |
| Not listed | Duarte | California | 91010 | — |
| Not listed | Oakland | California | 94611 | — |
| Not listed | Stanford | California | 94305 | — |
| Not listed | Denver | Colorado | 80218 | — |
| Not listed | New Haven | Connecticut | 06520 | — |
| Not listed | West Hartford | Connecticut | 06119 | — |
| Not listed | Miami Beach | Florida | 33140 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Harvey | Illinois | 60426 | — |
| Not listed | Springfield | Illinois | 62794-9677 | — |
| Not listed | Goshen | Indiana | 46526 | — |
| Not listed | Indianapolis | Indiana | 46237 | — |
| Not listed | Sioux City | Iowa | 51101 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | New Orleans | Louisiana | 70112 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Ann Arbor | Michigan | 48106 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Saint Cloud | Minnesota | 56303 | — |
| Not listed | Jackson | Mississippi | 39202 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Albuquerque | New Mexico | 87131-0001 | — |
| Not listed | Abany | New York | 12208 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Eugene | Oregon | 97401-8122 | — |
| Not listed | Easton | Pennsylvania | 18045 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Pittsburgh | Pennsylvania | 15212 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Charlottesville | Virginia | 22908 | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Urothelial Carcinoma trials
Other public records listing Urothelial Carcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT04895709: A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors Recruiting
- NCT07705035: DBC-664 in Adult Patients With Solid Tumors Recruiting
- NCT07169734: A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting
- NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Active, not recruiting
- NCT06101290: Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) Recruiting
- NCT02717156: Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02589717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02589717 live on ClinicalTrials.gov.